18-F-Fluoroacetate as PET Imaging Agent

NCT01320787 | Withdrawn Phase 1

• 2 other identifiers: 2009-0157NCI-2011-01066
• Study Type: interventional
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

The goal of this clinical research study is to find out the highest tolerable dose of an imaging solution called 18-F-fluoroacetate sodium that can be given before a positron emission tomography (PET) scan. The safety of this solution will also be studied.

Conditions

Brain Cancer; Breast Cancer; Prostate Cancer

Keywords

Brain; Adenocarcinoma of the prostate; Locally advanced breast cancer; Estrogen receptor; ER; Progesterone receptor; PR; Negative for ErbB2; Malignant tumor of the central nervous system; CNS

Outcome Measures

Primary Outcomes (1)

• Biodistribution of 18F-Fluoroacetate

  Biodistribution of 18F-fluoroacetate is measured during imaging, using a radioisotope (18F) of fluoroacetate PET scan. The percent injected dose (%ID) obtained in different organs derived from the PET data.

  1 day

Study Arms (1)

18F-fluoroacetate

EXPERIMENTAL

18F-fluoroacetate injection as a single intravenous bolus with a maximum volume of 4 mL followed by a saline flush of 20 to 50 mL.

Drug: 18F-fluoroacetate

Interventions

18F-fluoroacetate DRUG

18F-fluoroacetate injection as a single intravenous bolus with a maximum volume of 4 mL followed by a saline flush of 20 to 50 mL.

18F-fluoroacetate

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients must have: a) Histologic or cytologic confirmation of adenocarcinoma of the prostate; or b) A histologically confirmed, treatment-naïve, locally advanced breast cancer that express either estrogen receptor (ER) or progesterone receptor (PR) and are negative for ErbB2 by Immunohistochemistry (IHC) and/or fluorescence in situ hybridization (FISH) gene amplification; or c) Suspected supratentorial malignant primary or secondary malignant tumor of the central nervous system (CNS).
• The Eastern Cooperative Oncology Group (ECOG) Performance Status 0 - 2 or Karnofsky Performance Status of ≥ 60.
• Four weeks or greater since major surgery.
• Required Initial Laboratory Data: a) White Blood Count (WBC) \>/= 3,000/microliters. b) Absolute neutrophil count (ANC) \>/= 1,500/microliters. c) Platelet count \>/= 100,000/microliters. d) Creatinine \</= 1.5 x upper limit of normal e) Bilirubin \</= 2 x upper limit of normal (exceptions will be made for patients with Gilbert's Disease). f) SGOT (AST) \</= 2.5 x upper limit of normal. g) SGPT (ALT) \</= 2.5 x upper limit of normal.
• Subjects must be at least 18 years of age
• All sexually active subjects of child-bearing potential (CBP) must agree to use adequate contraception (hormonal or barrier method of birth control) for the duration of study participation from signing of consent till 30 days post injection. Should a male patient's sexual partner become pregnant or suspects that she is pregnant while the patient is participating in the study, the treating physician should be notified immediately. Female subjects of CBP must have a negative serum pregnancy test within 24 hours prior to the administration of the protocol imaging agent.
• For patients with adenocarcinoma of the prostate, they must have radiographic evidence of metastatic prostate cancer; measurable lymph node disease on either CT scan, MRI with any level of serum PSA. (There is no limitation of the type or numbers of prior chemotherapy regimens, palliative radiotherapy or other non-chemotherapy or hormonal therapies for metastatic disease.)
• For subjects with breast cancer, they must have local disease evaluated by standard breast imaging before initiation of treatment and no evidence of metastatic disease.
• For subjects with a recent biopsy of newly diagnosed high-grade tumor, they must have recovered from the effects of surgical biopsy. It must be at least \>/= 7 days after a brain biopsy to be eligible.
• Patients must have signed an informed consent document stating that they understand the investigational nature of the proposed imaging agent.
• Baseline imaging of all tumor types must be within 21 days of protocol PET imaging day, but more than 24 hours prior to the protocol PET imaging tracer administration. Patients can receive other standard diagnostic imaging procedures 24 hours post protocol PET imaging day.

You may not qualify if:

• Patients with significant cardiovascular disease including congestive heart failure (New York Heart Association Class III or IV), active angina pectoris or recent myocardial infarction (within the last 6 months) are excluded.
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
• History of allergic reactions attributed to compounds of similar chemical or biologic composition (i.e. 18F-FDG)
• Patients may not be receiving any other investigational agents while on this protocol.
• Patients with prostate cancer may not be receiving dutasteride or finasteride up to 2 weeks prior to enrollment.
• Patients who have received prior cytotoxic, biologic, hormonal (other than for replacement) therapy to treat the breast cancer. (Patients may continue on a daily Multi-Vitamin and any other herbal, alternative or food supplements.)
• Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g., infectious disease) illness must not be enrolled into the study.
• Patients with metastatic adenocarcinoma of the prostate documented by bone scan alone, are ineligible.
• Sexually active fertile men not using effective birth control if their partners are women of childbearing potential (WOCBP).
• Women who are pregnant, not using effective birth control or lactating are ineligible
• The subject is unable to lie down for 150 minutes.
• The subject suffers from claustrophobia.
• The subject has a history of serious hypersensitivity reaction to iodinated contrast media.

Sponsors & Collaborators

• M.D. Anderson Cancer Center: lead

Related Links

• University of Texas MD Anderson Cancer Center Website

MeSH Terms

Conditions

Brain Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Central Nervous System Neoplasms

Interventions

fluoroacetic acid

Condition Hierarchy (Ancestors)

Nervous System Neoplasms; Neoplasms by Site; Neoplasms; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases; Genital Neoplasms, Male; Urogenital Neoplasms; Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Prostatic Diseases; Male Urogenital Diseases

Study Officials

• Donald Podoloff, MD, BA

  M.D. Anderson Cancer Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 21, 2011
• First Posted: March 22, 2011
• Study Start: October 1, 2014
• Primary Completion: October 1, 2016
• Last Updated: October 23, 2014

Record last verified: 2014-10